Why 25–100 mg Works as a Sleep Drug: Receptor Occupancy, Half-Life and What Trials Show
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI).
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At low doses, 5-HT2A, alpha-1 adrenergic and H1 histamine blockade dominate, which promotes sleepiness. Serotonin transporter inhibition requires roughly 150–300 mg, the range used in major depression trials [1][9]. This receptor split explains why a 50 mg tablet at bedtime sedates but does not treat depression reliably on its own.
Immediate-release trazodone reaches peak plasma levels in about 1–2 hours on an empty stomach, and food delays the peak by roughly an hour. Elimination half-life is about 5–9 hours, and the active metabolite m-CPP is formed through CYP3A4 [9]. Next-morning grogginess is therefore plausible, particularly with 100 mg doses or with CYP3A4 inhibitors. Taking it 30–60 minutes before bed fits this profile [5][9].
A 2024 CNS Drugs meta-analysis reported improved subjective sleep quality and sleep onset, with mixed polysomnography findings [5]. Cochrane reviewers found low-to-moderate certainty for antidepressants in insomnia and limited long-term evidence [6]. Network meta-analyses place orexin antagonists and Z-drugs ahead on short-term efficacy [2][7]. For patients with coexisting depression or anxiety, trazodone may be a reasonable pick [1].
Low-dose trazodone (25–100 mg at bedtime) works mainly by blocking 5-HT2A, alpha-1 and H1 receptors. The 150–300 mg range needed for serotonin reuptake inhibition is not reached, so the effect is sedative rather than antidepressant.